~~NOVEL METHOD FOR THE PREPARATION OF GRANULATES OF ACTIVE CONSTITUENTS, AND GRANULATES AS OBTAINED.~~

The present invention relates to a novel method for the preparation of granulates of active constituents, as well as the granulates as obtained.

Numerous active constituents have pharmacokinetic profiles which involve a reduction in their efficacy, for example, in the case of a short half-life and/or a high plasma concentration peak and/or rapid elimination and/or low bioavailability.

Such pharmacokinetic profiles involve the administration of large daily doses and/or concomitant administrations repeated throughout the day, and also a limited efficacy owing to the great variations in plasma concentration and a risk of intolerance due to those same variations. In addition, this is prejudicial to the observance of the treatment.

There is therefore currently a need for the development of a galenic form bringing an improvement to that profile and reducing the number of administrations of medicaments, by enabling several active constituents to be combined within the same unit.

An object of the present invention is to provide a method for the preparation of a novel galenic form enabling the above-mentioned disadvantages to be avoided.

Thus, an object of the present invention is to provide a novel galenic form enabling the daily dose and the number of daily administrations to be reduced, by increasing the

NOVEL METHOD FOR PREPARING GRANULATES OF ACTIVE PRINCIPLES, AND GRANULATES OBTAINED THEREOF

The present invention relates to a novel method for the preparation of granulates of active constituents, as well as the granulates as obtained.

Numerous active constituents have pharmacokinetic profiles which involve a reduction in their efficacy, for example, in the case of a short half-life and/or a high plasma concentration peak and/or rapid elimination and/or low bioavailability.

Such pharmacokinetic profiles involve the administration of large daily doses and/or concomitant administrations repeated throughout the day, and also a limited efficacy owing to the great variations in plasma concentration and a risk of intolerance due to those same variations. In addition, this is prejudicial to the observance of the treatment.

There is therefore currently a need for the development of a galenic form bringing an improvement to that profile and reducing the number of administrations of medicaments, by enabling several active constituents to be combined within the same unit.

An object of the present invention is to provide a method for the preparation of a novel galenic form enabling the above-mentioned disadvantages to be avoided.

Thus, an object of the present invention is to provide a novel galenic form enabling the daily dose and the number of daily administrations to be reduced, by increasing the